Dr. Puhlmann has worked in oncology drug development for 20 years, and worked as the franchise head of global clinic development at Seagen. He also held positions with Merck & Co, Schering Plough, Bayer and Amgen and the National Cancer Institute.
“The opportunity to lead the development of Viewpoint’s pipeline programs is extremely exciting for me as a cancer drug developer. I think the application of targeted alpha-particle therapy will have a profound impact on the treatment of oncology patients,” Dr. Puhlmann said in an Oct. 4 press release.
